Short Interest in NewAmsterdam Pharma (NASDAQ:NAMSW) Drops By 40.8%

NewAmsterdam Pharma (NASDAQ:NAMSW) was the target of a large decrease in short interest during the month of June. As of June 15th, there was short interest totaling 42 shares, a decrease of 40.8% from the May 31st total of 71 shares. Based on an average daily trading volume, of 1,378 shares, the short-interest ratio is currently 0.0 days.

NewAmsterdam Pharma Trading Up 0.5%

NAMSW stock traded up $0.12 during mid-day trading on Thursday, hitting $23.55. 1,000 shares of the company were exchanged, compared to its average volume of 1,862. The business has a 50 day simple moving average of $22.14 and a 200-day simple moving average of $22.22. NewAmsterdam Pharma has a 1-year low of $8.41 and a 1-year high of $30.45.

Institutional Trading of NewAmsterdam Pharma

A hedge fund recently bought a new stake in NewAmsterdam Pharma stock. Aristeia Capital L.L.C. acquired a new stake in NewAmsterdam Pharma (NASDAQ:NAMSW) during the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor acquired 15,708 shares of the company’s stock, valued at approximately $397,000.

About NewAmsterdam Pharma

NewAmsterdam Pharma, Inc is a clinical-stage biotechnology company focused on the development of orally delivered peptide therapeutics for the treatment of metabolic diseases. Drawing upon proprietary peptide chemistry and formulation technologies, the company aims to transform injectable treatments for conditions such as type 2 diabetes, obesity and related cardiometabolic disorders into convenient, once-daily oral medications. By harnessing advances in peptide stabilization and targeted delivery, NewAmsterdam Pharma seeks to improve patient adherence and expand access to novel therapies.

The company’s lead program is an oral glucagon?like peptide?1 (GLP-1) receptor agonist currently in early clinical trials.